Skip to main content
. Author manuscript; available in PMC: 2007 Dec 12.
Published in final edited form as: J Immunother. 2006;29(4):455–463. doi: 10.1097/01.cji.0000208259.73167.58

TABLE 5.

Pharmacokinetics of Anti–CTLA-4 Antibody Administration

Sample Timepoint N Antibody Concentration (μg/mL)
Pretreatment 13 BD
Post 3 mg/kg × 1 5 55.8 ± 6.1
Pre 3 mg/kg × 2 3 17.4 ± 2.9
Post 3 mg/kg × 2 2 116.2 ± 15.4
Pre 5 mg/kg 4 25.5 ± 1.3
Post 5 mg/kg × 1 3 131.5 ± 66.8
Pre 5 mg/kg × 2 4 29.6 ± 9.3
Post 5 mg/kg × 2 3 193.1 ± 30.7
Pre 9 mg/kg 10 48.0 ± 4.9
Post 9 mg/kg × 1 3 287.0 ± 109.8
Pre 9 mg/kg × 2 5 60.0 ± 12.4
Post 9 mg/kg × 2 3 366.4 ± 28.6
Pre 9 mg/kg × 3 5 63.7 ± 8.6
Post 9 mg/kg × 3 4 342.8 ± 68.2
Pre 9 mg/kg × 4 2 68.9 ± 7.3
Post 9 mg/kg × 4 3 356.3 ± 74.2

Reported as the mean concentration ± the standard error of the mean.

BD indicates below detection.